Sorafenib(Nexavar) is an oral agent that is currently approved by the U.S. Food and Drug Administration for the treatment of kidney cancer. Several trials were began based on pre-clinical findings. A recent trial suggests that it is ineffective: “Sorafenib does not show sufficient activity as a single agent in first-line metastatic urothelial cancer to warrant further investigation.” It is in active trials, for example: Sorafenib in Urothelium Cancer of Bladder, NCT01215266 as well as with radiation.
Srikala S. Sridhar, Eric Winquist, Andrea Eisen, Sebastien J. Hotte, Elaine McWhirter, Ian F. Tannock, Som D. Mukherjee, Lisa Wang, Chantale Blattler and John J. Wright, et al.
A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium Investigational New Drugs DOI: 10.1007/s10637-010-9408-4, 2010